Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 epratuzumab study in moderate to severe systemic lupus erythematosus
ACTRN12611000464965Phase 3Recruiting
- Sponsor
- UCB
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of epratuzumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by UCB. Primary endpoint: Percent of subjects meeting combined response index response criteria at Week 48. Started Jan 2011; status: recruiting.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ACTRN12611000464965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000464965.